|
Hemangiosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report.
|
31805975 |
2019 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ancillary techniques are, in general, of little help for separating the borderland cases but, in some instances, immunohistochemical study (IHC) for Ki67 and IHC or fluorescence in situ hybridization analysis for MYC may help in the diagnosis of angiosarcoma.
|
30251277 |
2019 |
|
Hemangiosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recurrent MYC amplifications (96%) and KDR variants (8%) were detected in post-radiation angiosarcomas, in agreement with the literature.
|
31243333 |
2019 |
|
Hemangiosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It has been shown convincingly, that the majority of radiation-associated angiosarcomas are characterised by amplification and subsequent overexpression of MYC in contrast to benign and atypical vascular lesions.
|
28983701 |
2018 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MYC amplification was not detected in any of the 5 cases examined, aiding in ruling out the possibility of angiosarcoma.
|
29104110 |
2018 |
|
Hemangiosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IHC detected MYC overexpression in 8 of 15 informative cases (7 secondary AS and 1 idiopathic AS).
|
29135507 |
2018 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report MYC amplification in two cases of angiosarcoma arising in massive chronic lymphedema of morbid obesity.
|
27686553 |
2017 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the mechanisms of cellular injury and repair resulting from ionizing radiation are well described, the genomics of radiation-induced tumours are still relatively poorly understood, with some exceptions, such as RET rearrangement in thyroid carcinomas following iodine-131 exposure and MYC amplification in cutaneous angiosarcoma following chest wall irradiation for breast cancer.
|
27960236 |
2017 |
|
Hemangiosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Most radiation-induced AS show MYC gene amplifications, with a subset of cases harboring KDR, PTPRB, and PLCG1 mutations.
|
26735859 |
2016 |
|
Hemangiosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genetic characterization of several soft tissue tumour types that occur in the skin has resulted in the identification of diagnostically useful markers: ALK gene rearrangement with corresponding ALK protein expression by immunohistochemistry in epithelioid fibrous histiocytoma; the WWTR1-CAMTA1 fusion gene with CAMTA1 protein expression in epithelioid haemangioendothelioma; MYC amplification and overexpression in radiation-associated angiosarcoma; and EWSR1 gene rearrangement in cutaneous myoepithelial tumours.
|
26763770 |
2016 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Survival analysis of the SAS patients demonstrates that those with MYC amplification had a significantly worse overall survival compared to cases without MYC amplification (P = 0.035).
|
25893585 |
2015 |
|
Hemangiosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The genetic bases of these tumors have been partially revealed in recent studies reporting genetic alterations such as amplifications of MYC (primarily in radiation-associated angiosarcomas), inactivating mutations in PTPRB and R707Q hotspot mutations of PLCG1.
|
26440310 |
2015 |
|
Hemangiosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MYC protein expression and gene amplification have been detected in secondary angiosarcoma (AS), and a subset of primary AS.
|
26223194 |
2015 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, possible involvement of MYC and KDR has been documented in a subset of angiosarcomas of soft tissue.
|
25231439 |
2015 |
|
Hemangiosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Specifically, this article will focus on the following aspects: (1) pathological and molecular features of epithelioid hemangioendothelioma, including the more common WWTR1-CAMTA1 fusion, as well as the recently described YAP1-TFE3 fusion, identified in a morphological variant of epithelioid hemangioendothelioma; (2) discuss the heterogeneity of angiosarcoma clinical, morphological and genetic spectrum, with particular emphasis of MYC and FLT4 gene amplification in radiation-induced angiosarcoma; and (3) provide a practical guide in the differential diagnosis of epithelioid vascular tumors using molecular testing.
|
24384851 |
2014 |
|
Hemangiosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
By IHC analysis, MYC overexpression was present in 9/38 (24%) AS-C (2-3+: 6 cases, 16%; 1+: 3 cases, 8%).
|
24091875 |
2014 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also found MYC amplification in 1 primary skin AS and 1 primary cardiac AS.
|
24457083 |
2014 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Key roles for MYC, KIT and RET signaling in secondary angiosarcomas.
|
24983371 |
2014 |
|
Hemangiosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MYC amplification and expression of the corresponding protein has been identified in AS in comparison with AVL.
|
24113311 |
2013 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found significantly higher numbers of MYC amplifications in RIS than in sporadic sarcomas (P < 0.0001), especially in angiosarcomas, undifferentiated pleomorphic sarcomas, and leiomyosarcomas.
|
23012233 |
2013 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of note, however, no c-myc gene abnormalities have been demonstrated in cases of primary angiosarcomas or postradiation atypical vascular lesions.
|
23221487 |
2013 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the presence of MYC amplification represents an important additional diagnostic tool in the distinction of postradiation cutaneous angiosarcomas from atypical vascular lesions after radiotherapy.
|
21909081 |
2012 |
|
Hemangiosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Amplification of MYC and nuclear expression of MYC is present in secondary angiosarcoma but not AVL.
|
22121953 |
2012 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, MYC amplification may play a crucial role in the angiogenic phenotype of AS through upregulation of the miR-17-92 cluster, which subsequently downregulates THBS1, a potent endogenous inhibitor of angiogenesis.
|
22383169 |
2012 |
|
Hemangiosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings reinforce the distinct pathogenesis of AS subtypes, with MYC amplification being an early, but necessary event in secondary AS.
|
20949568 |
2011 |